Erosion regression in patients with rheumatoid arthritis after upadacitinib—a pilot study using high resolution peripheral quantitative computed tomography
Authors' conclusion
Despite a similar improvement in RA disease activity after upadacitinib compared with csDMARDs, a differential regression of erosion on HR-pQCT was observed in patients received upadacitinib.
Study context
- Population
- Adults with active RA with ≥1 bone erosion on high-resolution peripheral quantitative CT (HR-pQCT)19 upadacitinib completed
- Comparison
- Upadacitinib 15 mg once daily for 24 weeks vs csDMARDs
- Upadacitinibn = 20
- Controln = Twentyreference
- Primary endpoint
- Erosion volume change on HR-pQCT of the metacarpophalangeal joint
- Follow-up
- 24 weeks
Methodological detailsnon-randomized, age-and-sex matched active controls
- Non-randomized
- Age-and-sex matched active controls
Primary result
As reported in the abstract
Mean erosion volume change on HR-pQCT
Upadacitinib
−0.23
mean · ± 3.26 · mm³
Control
1.32
mean · ± 6.05 · mm³
P = 0.131
Further findings
Proportion of erosions with regression · 24 weeks
P = 0.085
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Erosion regression (GEE, adjusted for disease duration) · 24 weeksAdjusted for difference in disease duration | 3.61 (1.00–13.00) | P = 0.049 | |
| 0.050.21520Odds ratio (log scale) |
Disease activity · 24 weeks
- Similar improvement in disease activity in both groups
Serum bone resorption markers
- Reduced after upadacitinib treatment
Original publication
Erosion regression in patients with rheumatoid arthritis after upadacitinib—a pilot study using high resolution peripheral quantitative computed tomography. Rheumatology (Oxford). Published 17 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →